Evercore ISI analyst Joshua Schimmer downgraded Seagen (SGEN) to In Line from Outperform with a price target of $229, up from $175, after Pfizer (PFE) announced a deal to acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGEN: